PRL and neoplasm: We associated ANA to a reduced dose of CAB (3.5 mg/week): the patient achieved a PRL leverel reduction (145 μg/L) in 3 months, with a nadir of 50 μg/L, and a consistent shrinkage in tumor volume (see Fig. 1).